Author

Daniel Byrom

Institute for Research in Biomedicine

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

Ana Raquel HenriquesiD· 1 shared Antoni RiéraiD· 1 shared Carolina SáncheziD· 1 shared Daniele V. F. TaurielloiD· 1 shared Eduard BatlleiD· 1 shared Elena SanchoiD· 1 shared Irene RuanoiD· 1 shared Israel RamosiD· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

Ana Raquel HenriquesORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

HYL001, a new potent TGFβ signaling inhibitor that is efficacious against microsatellite stable CRC metastasis in combination with immune checkpoint therapy in mice

Daniele V. F. Tauriello, Elena Sancho, Daniel Byrom, Carolina Sánchez, Maria Salvany, Ana Raquel Henriques, Sergio Palomo‐Ponce, Marta Sevillano, Xavier Hernando‐Momblona, Joan A. Matarin, Israel Ramos, Irene Ruano, Neus Prats, Eduard Batlle, Antoni Riéra

This paper describes the development of HYL001, a TGFβ inhibitor that effectively combats microsatellite stable CRC metastasis in mice when combined with immune checkpoint therapy.

ACS Pharmacology & Translational Science · Oct 1, 2024Peer-reviewedPharmacology & Toxicology